Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors
ConclusionsrFIXFc prophylaxis provides improved health outcomes and lower costs, and represents a cost-effective treatment option compared with rFIX on-demand for adolescent and adult male patients with haemophilia B. This comparative assessment of cost-effectiveness should help to inform both clinicians and healthcare policy makers when making treatment decisions for patients with haemophilia B.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Bleeding | Children | Drugs & Pharmacology | Haemophilia | Hemophilia | Italy Health | Study